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Background: The Diabetes Prevention Program (DPP) study showed that lifestyle intervention resulted in a 58%
reduction in incidence of type 2 diabetes among individuals with prediabetes. Additional large randomized
controlled trials have confirmed these results, and long-term follow-up has shown sustained benefit 10–20 years
after the interventions ended. Diabetes is a common and costly disease, especially among Veterans, and despite
strong evidence supporting the feasibility of type 2 diabetes prevention, the DPP has not been widely implemented.
The first aim of this study will evaluate implementation of the Veterans Affairs (VA) DPP in three VA medical centers.
The second aim will assess weight and hemoglobin A1c (A1c) outcomes, and the third aim will determine the
cost-effectiveness and budget impact of implementation of the VA DPP from a health system perspective.
Methods/Design: This partnered multi-site non-randomized systematic assignment study will use a highly pragmatic
hybrid effectiveness-implementation type III mixed methods study design. The implementation and administration of
the VA DPP will be funded by clinical operations while the evaluation of the VA DPP will be funded by research grants.
Seven hundred twenty eligible Veterans will be systematically assigned to the VA DPP clinical demonstration or the
usual care VA MOVE!® weight management program. A multi-phase formative evaluation of the VA DPP implementation
will be conducted. A theoretical program change model will be used to guide the implementation process and assess
applicability and feasibility of the DPP for VA. The Consolidated Framework for Implementation Research (CFIR) will be
used to guide qualitative data collection, analysis, and interpretation of barriers and facilitators to implementation. The
RE-AIM framework will be used to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance of the VA
DPP. Twelve-month weight and A1c change will be evaluated for the VA DPP compared to the VA MOVE! program.
Mediation analyses will be conducted to identify whether program design differences impact outcomes.
Discussion: Findings from this pragmatic evaluation will be highly applicable to practitioners who are tasked with
implementing the DPP in clinical settings. In addition, findings will determine the effectiveness and cost-effectiveness
of the VA DPP in the Veteran population.
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Preventing diabetes
The Diabetes Prevention Program (DPP) study showed
that lifestyle intervention resulted in a 58% reduction in
incidence of type 2 diabetes among individuals with
prediabetes [1]. Additional large randomized controlled
trials have confirmed these results [2-4], and long-term
follow-up has shown sustained benefit 10–20 years after
the interventions ended [3,5]. Table 1 lists published type
2 diabetes prevention clinical trials and their results. These
trials provide a strong evidence base for large-scale dis-
semination and implementation of the DPP to prevent
type 2 diabetes.
One significant barrier to implementing the DPP is the
high cost of the individualized program. However, recent
studies have shown that the program can be delivered at
a lower cost in group sessions with comparable effective-
ness [6,7]. For example, the Group Lifestyle Balance
(GLB) program, a group-based adaptation of the DPP
curriculum developed by the Diabetes Prevention Sup-
port Center (DPSC) of the University of Pittsburgh, re-
sulted in clinically significant weight loss 12 months
after baseline among program participants that com-
pleted the 12-month assessment [7,8]. GLB retains many
of the components of the DPP, including standardized
goals for weight loss, diet, and exercise and incremental
introduction of self-regulation skills with a goal of self-
regulation skill mastery.
Despite strong evidence supporting the feasibility of
type 2 diabetes prevention, Veterans continue to be at
high risk for developing type 2 diabetes. Primarily be-
cause of the older age of the population, the prevalenceTable 1 Published diabetes prevention program trial descript
Study Individual
or group
N (lifestyle gro
The Diabetes Prevention Program
study [1]
Individual 1,079
Diabetes Prevention Program
Outcomes study [5]
Individual 910
The Finnish Diabetes Prevention
Program study [42]
Individual 265
China Da Qing Diabetes
Prevention study [3]
Individual 266c
Indian Diabetes Prevention
Programme [4]
Advice to individuald 133e
DEPLOY YMCA [6] Group 29
Group Lifestyle Balance [7] Group 52g
aFollow-up ranged from 1.8–4.6 years.
bThere was a 43% reduction in relative risk at a median of 7 years of follow-up; afte
free of diabetes were further followed up for a median of 3 years [43].
cNumber of participants, combined, across three lifestyle interventions: diet, exercis
dParticipants received advice on healthy diet and regular physical activity.
eOne hundred and thirty-three individuals were randomized to this intervention bu
fParticipants were younger (mean age 45.9 ± 5.7 years) and had lower BMI (25.8 ± 3
gNumber of participants that completed the 12-month assessment in a single groupof type 2 diabetes is higher among Veterans who obtain
care in the Veterans Affairs (VA) healthcare system than
that in the general population, affecting approximately
one in four Veterans [9]. In 2011, the Centers for Disease
Control and Prevention (CDC) launched a national ini-
tiative to increase access to evidence-based DPP inter-
ventions for individuals with prediabetes [10], which
contributed to the impetus for the current Veterans
Affairs Diabetes Prevention Program (VA DPP) clinical
demonstration.
Preventing diabetes among Veterans
The VA National Center for Health Promotion and
Disease Prevention (NCP) is the VA’s national program
office responsible for many national disease prevention
efforts. In 2006, NCP led the unprecedented implemen-
tation of VA MOVE!®, a national weight loss program
within the VA [11]. VA MOVE! is an evidence-based,
multi-disciplinary, comprehensive weight management
program [11-14]. The core program includes eight to
ten face-to-face small group sessions, led by a multi-
disciplinary team of nutritionists, health psychologists,
and physical therapists. While many elements of VA
MOVE! are comparable to the VA DPP, Table 2 lists pro-
gram design differences between the VA DPP and VA
MOVE!. Additional file 1 provides further details. Within
VA, over 95% of Veterans are screened for obesity, pro-
vided with obesity counseling, and offered VA MOVE!
or another weight management program, as clinically
appropriate [15,16]. Veterans are candidates for VA
MOVE! if their body mass index (BMI) is greater than
30 kg/m2 or greater than 25 kg/m2 with one obesity-ions and selected outcomes
up) Years of
follow-up
Mean weight loss
(lifestyle group)
Reduction in developing
diabetes
2.8a 5.6 kg 58%
10 2.0 kg 34%
2 3.5 kg 58%b
20 3.7 kg 43%
3 No significant change
in body weightf
28.5%
1 5.7 kg (6%) NA
1 5.5 kg (5.5%) NA
r a median of 4 years of active intervention period, participants who were still
e, and diet plus exercise.
t 120 were available for follow-up at 2.5 years.
.5 kg/m2) than previous studies.
pre-post comparison study.
Table 2 Program design differences between the VA DPP and VA MOVE!
Program attribute VA DPP VA MOVE! Behavioral constructs
impacted
Goal awareness and
commitment
Assigned generic goals Patients create own goals Goal awareness
Goal commitment
Outcome expectations Focus on diabetes prevention Focus on weight loss and healthy lifestyle Perceived risk [44]
Outcome expectations [45]
Intrinsic/extrinsic motivation [46]
Group cohesion Closed cohorts, single coach,
group identity around prediabetes
Open and closed cohorts, multi-disciplinary
team, individuals with diabetes, prediabetes
and normal glucose tolerance in the
same group
Group cohesion
Attitude toward others in group
Attitude toward the group
coach
Self-regulation skill mastery Iterative skill building and a focus
on mastery
Independent sessions addressing a series
of behavioral skills
Self-regulation skills [47]
Self-efficacy [47,48]
Willingness to self-monitor
Adherence to monitoring
Program intensity Sixteen sessions in 6 months Twelve to fourteen sessions in 3 months Attendance
Satisfaction with number of visits
Maintenance
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screened for prediabetes, and with only a few exceptions,
lifestyle modification programs that specifically target
individuals with prediabetes are not available in the VA.
Executive leaders identified the implementation of the
DPP in the VA as a top-priority clinical goal and gave
NCP the lead for the current initiative. In order to evalu-
ate the feasibility of implementing a group-based DPP in
the VA, NCP will conduct a clinical demonstration of
the DPP at three VA medical centers across the country,
hereafter referred to as the VA DPP. NCP requested the
assistance of the research coordinating center to conduct
a comprehensive and rigorous evaluation of the imple-
mentation of the VA DPP in preparation for potential
national dissemination as well an evaluation to deter-
mine effectiveness of the VA DPP in the Veteran popula-
tion. Each VA DPP site will screen and enroll Veterans
with prediabetes who have been referred to the VA
MOVE! program. A systematic assignment algorithm
will assign these Veterans either to the VA DPP or the
VA MOVE! program.
The VA DPP has been deemed a clinical quality im-
provement (QI) initiative. The implementation and ad-
ministration of the VA DPP will be funded by clinical
operations while the evaluation of the VA DPP will be
funded by research grants. Because of the extremely
short timeline, the research coordinating center submit-
ted two separate research proposals, which are detailed
in this protocol. Each research proposal was reviewed by
a national peer review panel. The first proposal was sub-
mitted as part of the Quality Enhancement Research
Initiative (QUERI) Rapid Response Project (RRP) program,which funds 1-year studies. This grant will enable the
research coordinating center to collect baseline data as
the VA DPP begins. The research coordinating center
then submitted a QUERI Service Directed Project (SDP),
which funds 2-year studies. This grant will enable the re-
search coordinating center to collect and analyze follow-
up data. Table 3 details the different funding sources and
institutional review board (IRB) approvals for evaluation
activities.
VA DPP design
The VA DPP will run multiple cohorts per site, with the
time intervals between the start of each cohort to be
determined by site capacity. Each VA DPP cohort will in-
clude a series of 22 face-to-face GLB sessions using GLB
materials, led by a coach with formal nutrition training
and prior lifestyle coaching experience [17]. Table 4 de-
tails eligibility criteria for the VA DPP. Details about
sample size and recruitment are provided under the
“Aim 2” section below.
VA DPP implementation strategy
The strategic framework for implementing the VA DPP
will be an adaptation of Simpson et al.’s theoretical pro-
gram change model for translating research into practice
[18]. Figure 1 illustrates components of this framework.
Organizational readiness to implement a new program
is demonstrated by stakeholders being internally moti-
vated or externally pressured for change, which results
in the allocation of resources necessary for implementa-
tion and administration of a new program [18]. The VA
DPP site leaders must show commitment to diabetes
Table 3 VA DPP funding sources and IRB approvals
Aims Data type Funding IRB approvals
Quantitative data
2 Weight and A1c lab results: baseline
and follow-up
NCP QIa Data collection approved as QI
SDPb Data access and analysis approved by five IRBsc
2, 3 Baseline patient surveys RRPd Approved by five IRBs
2, 3 Follow-up patient surveys SDP Approved by five IRBs
3 EQ5D survey RRP Approved by five IRBs
SDP
2, 3 Administrative utilization data linked to
patient survey data
SDP Approved by five IRBs for consented patients only
3 Staff time logs NCP QI Data collection approved as QI
Data access and analysis approved by the research coordinating
center’s IRB and the site conducting the cost analyses IRB
• Included as information only in IRB applications for sites
implementing the VA DPP
Qualitative data
1 Early implementation staff interviews NCP QI Data collection approved as QI
SDP Data access and analysis approved by the research coordinating
center’s IRB
• Included as information only in IRB applications for sites
implementing the VA DPP
1 Late implementation staff interviews,
site visit field notes
SDP Approved by the research coordinating center’s IRB
• Included as information only in IRB applications for sites
implementing the VA DPP
2 Patient interviews SDP Approved by the research coordinating center’s IRB
• Included as information only in IRB applications for sites
implementing the VA DPP
1 Fidelity assessments, meeting notes, document
artifacts (e.g., emails)
NCP QI Data collection approved as QI
SDP Data access and analysis approved by the research
coordinating center’s IRB
• Included as information only in IRB applications for sites
implementing the VA DPP
aQI: quality initiative funded by the National Center for Health Promotion and Disease Prevention (NCP).
bSDP: Service Directed Project funded by the VA Quality Enhancement Research Initiative (QUERI) program; 2 year grant (12–549).
cIRB: Institutional Review Boards are located at the three sites implementing the VA DPP, the research coordinating center, and the site conducting the cost analyses.
dRRP: Rapid Response Project funded by the VA QUERI program; 1 year grant (12–440).
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DPP. NCP will provide all three VA DPP sites with pro-
gram resources, including funding for staffing, training,
and program materials.
Phase one: adoption
In the VA DPP, exposure and training will take place
after each VA DPP site’s Medical Center Director signs a
formal memorandum of understanding (MOU) with
NCP to demonstrate their commitment to the program.
A clinical champion at each site will be responsible for
shepherding the MOU through the approval process.
This will require a series of presentations, conference
calls, and meetings to inform all levels of local leadership
about the VA DPP and to obtain a formal commitmentfrom senior leaders to visibly support the project. The
clinical champion will be responsible for hiring staff and
coordinating with other site-specific resource teams that
will be needed for the VA DPP, including the laboratory
and the medical records teams. NCP leadership will help
identify local supporters and provide visible authority
(e.g., phone calls to leaders) at each site to further
convey the importance of the project as it is being
implemented.
Phase two: training
All team members will be trained at a 2-day GLB train-
ing program offered by the DPSC at the University of
Pittsburgh. NCP will pay the costs for round-trip travel
and registration for the training.
Table 4 VA DPP eligibility criteria
Inclusion criteria Exclusion criteria
Patients will be considered VA DPP eligible if all of the below are
true:
Patients will be considered VA DPP ineligible if one or more of the following is
true:
Patient has fasting glucose of 100–125 mg/dl OR A1c of 5.7%–6.4%
for the past 6 months.
Patient already has type 2 diabetes. If patient was ever diagnosed with diabetes,
they are not eligible, even if their A1c level is within the eligible range; they are
then considered “diet controlled”.
Note: This is NOT the same as the VA’s criteria, which considers
prediabetes as 5.7%–6.9%. Patient does not have laboratory-confirmed elevations in either fasting glucose
or A1c that indicates prediabetes.
Patient is VA MOVE! eligible (BMI ≥ 30 or BMI ≥ 25 with at least
one cardiovascular disease risk factor). Patient is taking metformin or other hypoglycemic agent.
Patient is currently known to be pregnant.Patient is competent to provide informed consent.
Patient has an eating disorder.
Patient understands English. Patient has a medical contraindication to diet, exercise, or weight loss.
Patient has not used metformin for the past 3 months. Patient is not competent to complete the informed consent process.
Travel time is <60 min from the VA medical center where
patient receives their care.
Patient has attended all or part of VA MOVE! in the last year.
Patient has completed VA MOVE! introduction class. Travel time is >60 min from the VA medical center where patient receives their care.
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VA DPP cohorts will run in parallel to existing VA
MOVE! groups. Implementation will rely on the existing
VA MOVE! infrastructure for obesity screening, program
referral, and medical clearance. Each site will develop a
site-specific protocol that aligns the new processes for
screening, identifying, informing, and assigning Veterans
to the VA DPP within the existing VA MOVE! infra-
structure. Protocols will also include processes for using
the electronic medical record (EMR) system to track
Veterans with prediabetes by VA DPP cohort. TheseOrganizational Readine
Motivation Resource
1. Exposure (Training
2. Adoption (Leadership De
3. Implementation (Explorato
4. Practice (Routine Us
PROGRAM CHANG
PROGRAM IMPROVEM
Figure 1 VA DPP strategic framework for implementation.institutional supports will be essential for monitoring
and providing feedback to ensure successful implemen-
tation and administration of the VA DPP. The research
coordinating center will facilitate weekly calls with VA
DPP staff from each site to get status updates and provide
collective problem-solving support during the implemen-
tation process.
Phase four: sustainability (routine use)
If the VA DPP is found feasible and effective, the challenge
will be to sustain the program at each site and disseminatess
s
)
cision)
ry Use)
e)
E
ENT
Staff, time, and 
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Institutional 
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study is to provide recommendations to NCP about how
to scale-up the VA DPP, or its more successful compo-
nents, at a national level.Research study aims
The research study design will follow the structure of an
effectiveness-implementation hybrid type III trial [19].
Because of the strong evidence base for the DPP, the pri-
mary aim of this study will facilitate and evaluate imple-
mentation of the VA DPP at the three sites. However,
because the DPP has not yet been evaluated in a Veteran
population, the second aim will assess weight and he-
moglobin A1c (A1c) outcomes for Veterans who enroll
in the VA DPP. The third aim will determine the cost-
effectiveness and budget impact of implementation of
the VA DPP from a health system perspective. Specific-
ally, the research study aims are:Aim 1
The first aim is to evaluate an implementation strategy
and identify barriers and facilitators to implementation
of the VA DPP at three VA medical centers.Aim 2
The second aim is to evaluate the effect of program imple-
mentation on participant outcomes, specifically weight
and A1c values at 12 months, in the VA DPP compared to
VA MOVE!, and assess patient engagement and adherence
in the VA DPP.Aim 3
The third aim is to conduct cost-effectiveness and
budget impact analyses of implementing the VA DPP in
the VA from the health system perspective.Figure 2 Formative evaluation framework: integration of RE-AIM and the CMethods
In this section, the VA DPP evaluation aims, study par-
ticipants, data collection procedures, and analysis plans
will be described for each study aim.
Aim 1: implementation evaluation
This study will not be sufficiently powered to quantita-
tively assess site-specific factors that may influence imple-
mentation outcomes. Therefore, this study will conduct a
mixed methods, multi-dimensional, formative evaluation
of the implementation strategy. This formative evaluation
will incorporate the following features: 1) developmental
evaluation to identify barriers and facilitators to imple-
mentation; 2) implementation and progress-focused eva-
luation to actively monitor implementation progress and
adapt the program as needed; and 3) interpretive evalu-
ation to provide detailed information on success or failure
of implementation [20]. If the program is effective in the
Veteran population, findings will be used to develop rec-
ommendations for disseminating the VA DPP more
broadly in the VA.
Evaluation framework
This study will integrate two published frameworks to
guide the formative evaluation: 1) the RE-AIM frame-
work [21] will be used to assess external validity and
prospects for dissemination and implementation of the
VA DPP in the VA and 2) the Consolidated Framework
for Implementation Research (CFIR) will be used to
systematically assess contextual factors that influence
adoption and implementation [22]. Figure 2 illustrates
the integration of RE-AIM and CFIR. Additional file 2
provides detailed research questions and quantitative
and qualitative measures for each of the RE-AIM
dimensions.
The CFIR will be used to guide a systematic evaluation
of barriers and facilitators that may affect adoption, im-
plementation, and/or maintenance. The CFIR comprisesFIR.
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influence implementation [23-25]. These constructs are
organized within five major domains: intervention char-
acteristics, outer and inner setting, characteristics of
individuals, and implementation process. Examples of
constructs include the relative advantage of the program
(intervention characteristics), patient needs and resources
(outer setting), networks and communications in the facil-
ity (inner setting), knowledge and beliefs of stakeholders
(characteristics of individuals), and engaging stakeholders
in the process (process).
Study participants
Participants will include VA DPP staff, VA MOVE!
program coordinators and staff, Health Promotion and
Disease Prevention (HPDP) program managers, Health Be-
havior Coordinators (HBC), primary care clinical leaders,
primary care providers, and other primary care staff at each
VA DPP site.
Data collection
Staff interviews The CFIR will be used to develop a
semi-structured interview guide and guide data collec-
tion. Additional file 3 provides copies of the staff inter-
view guides. Stakeholders (four to ten per site) will be
interviewed at early (or pre-) implementation and late
(or post-) implementation of the VA DPP. Interviews will
take place over the phone or in person during site visits
and will last 15–60 min. The early implementation inter-
views will assess receptivity to the VA DPP and identify
potential implementation barriers and facilitators. This
information will be used to develop tailored implemen-
tation and communication strategies for each site. The
late implementation interviews will elicit in-depth infor-
mation about experiences implementing and administer-
ing the VA DPP and to understand success or failure of
implementation. These interviews will explore prospects
for sustainability and inform broader dissemination and
implementation if the program is effective. In addition,
field notes, project meeting notes, and other artifacts
(e.g., emails) will be used throughout the course of the
study in order to identify and address barriers to imple-
mentation, refine the program, and provide feedback to
site staff.
Fidelity assessments Fidelity checklists will be com-
pleted for two VA DPP and two VA MOVE! sessions in
each cohort. The project coordinator will use the check-
list to rate each item and provide open-ended notes.
This approach will provide fidelity assessments of VA
DPP delivery and a comparison to VA MOVE! ses-
sions. Additional file 4 provides copies of the fidelity
checklists.Data analysis
Staff interviews The CFIR will be used as an organizing
framework for qualitative data coding and analysis.
Deductive and inductive content analyses, guided by a
consensus-based qualitative research approach [26,27],
will be conducted on all interview data using NVivo
qualitative analysis software. This analysis approach will
have the following features: 1) multiple judges will be
used throughout data analysis to foster multiple perspec-
tives; 2) consensual validation will be achieved through a
process of discussion and deliberation [28]; 3) an expert
auditor not integrally involved in the study will review
the process to help maximize validity of findings; and 4)
CFIR constructs will be identified and applied to cases,
and cross-analyses will be performed [29]. A summary
will be written for each facility based on data from ver-
batim interview transcripts and field notes with support-
ing quotes. Matrices will be constructed to help discern
patterns within and across facilities by comparing and
contrasting themes. Qualitative analysts will be blinded
to facility outcomes related to implementation effective-
ness until qualitative data analyses are completed. Full
information from all facilities will be used in the inter-
pretative phase, when qualitative findings will be com-
bined with quantitative data measuring implementation
effectiveness.
Fidelity assessments Fidelity ratings will be used to
compute average scores for coaching and delivery fidelity
domains. Simple t-test analyses will be used to assess
differences between the VA DPP and VA MOVE!.
Aim 2: effectiveness evaluation
This study will evaluate whether patient weight and A1c
outcomes are better in the VA DPP than those in VA
MOVE!. In addition, process measures will be assessed,
including the percentage of Veterans who engage in (at-
tend at least four sessions) and adhere to (attend at least
nine sessions) the VA DPP [30]. Careful attention will be
paid to discern whether there are significant differences
across important demographic sub-groups, such as gen-
der or race/ethnicity in program outcomes (weight and
A1c outcomes) or process measures (enrollment, en-
gagement, and adherence). Mediation analyses will also
be conducted to identify whether program design differ-
ences between the VA DPP and VA MOVE! impact
outcomes.
Study participants
Participants will include eligible Veterans who are referred
to VA MOVE! at each of the three VA DPP sites. Table 4
details eligibility criteria. Power analyses were conducted
to determine sample size needed to have 80% power to de-
tect expected differences in program outcomes with alpha
Table 5 Sampling strategy for patient semi-structured
interviews
Axis of diversity Strata
Program • VA DPP
• VA MOVE!
Level of participation • High participation
• Low participation
• No participation
Category of weight loss • High weight loss
• Low weight loss, maintenance,
or weight gain
Sex • Women
• Men
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assumed that the VA DPP would result in 1.7 additional
pounds of weight loss compared to VA MOVE! with a
standard deviation of 6.96 lbs (assuming a standard devi-
ation of 11 lbs and a within-person correlation of .8 for
weights at baseline versus 12 months) and assuming an
intra-group correlation coefficient of .014. Assuming that
20% of participants would drop out by 12 months, this
calculation indicated the need to recruit 720 patients
(360 for the VA DPP and 360 for VA MOVE!). Given
the sample size, the expected pace of recruitment, a
target of 20 participants per cohort, and the structure of
the existing VA MOVE! programs, six cohorts will be
conducted with a new cohort starting every 2 months.
Since randomization is not possible for this clinical
demonstration, a systematic assignment process will be
used; every 2 months, the first 20 patients who meet the
VA DPP eligibility criteria will be enrolled and assigned
to the VA DPP and the next 20 eligible patients will be
assigned to VA MOVE! by VA DPP site staff.
Data collection
Patient clinical outcomes Weight will be measured
with a medical-grade scale at each VA DPP and VA
MOVE! session as well as at a 12-month program-
specific session. Weight will also be routinely measured
and documented in the EMR during other VA clinical
visits. Baseline A1c and 12-month follow-up A1cs will
be ordered by providers or the VA DPP coaches. A1c
testing will occur via a laboratory blood draw or point of
care (POC) testing. Attendance at all VA DPP and VA
MOVE! sessions will be documented in the EMR by
program session leaders.
Patient surveys
Eligible Veterans will be invited to complete baseline sur-
veys after completing an informed consent process. Con-
sented Veterans will be given a paper copy of the survey
along with a business reply envelope addressed to the
research coordinating center. At 12 months, Veterans will
be invited to complete follow-up surveys. Survey instruc-
tions will include a web address that will link to an elec-
tronic version of the paper survey for Veterans who prefer
to answer the survey online. The surveys will measure
potential mediators of program outcomes, including per-
ceptions of goal awareness and commitment, outcome
expectations, group cohesion, self-regulation skill mastery,
and program intensity, as well as quality of life, satisfaction
with the program, sleep, social support, and depression.
Additional file 5 provides a copy of the program surveys.
Patient interviews
At 12 months, patients will be purposively selected for
interviews in order to maximize variation in programarm, participation, weight loss, and sex. Table 5 illustrates
the sampling strategy. Interviews will assess patient expe-
riences in the program. Additional file 6 provides a copy
of the patient interview guide.
Data analysis
Patient surveys and clinical outcomes Effects of the
VA DPP and VA MOVE! on patient outcomes at 12
months will be assessed using clinical weights and A1c
lab values. The distribution of all study variables and
baseline differences in factors that may affect study out-
comes between groups will be assessed. If significant
differences are found, they will be included as covariates
in the final analyses. At each assessment time, cross-
sectional means and their associated 95% confidence
intervals for continuous outcomes (e.g., weight) will be
described. Comparison between the VA DPP and VA
MOVE! in weight loss at 12 months will be completed
with a linear mixed-effects model, using program arm as
random intercepts to account for potential intra-
program group correlation. The model will include the
primary predictor of program arm (the VA DPP or VA
MOVE!), indicators for the three study sites, baseline
weight values, and age, sex, and race variables. Time-
averaged effects of the VA DPP over VA MOVE! will be
compared using weight loss at 12 months as the
dependent variable. The model will allow the use of
all available data, even if some Veterans are missing
12-month weights, and will give an unbiased estimate
as long as missingness does not depend on the unob-
served missing outcomes. Careful graphical analyses of
longitudinal outcome data will be completed to ensure
that an appropriate and meaningful longitudinal model is
created. Additional file 7 describes the planned mediation
analyses.
Patient interviews Inductive content analysis, guided
by a consensus-based qualitative research approach, will
Damschroder et al. Implementation Science  (2015) 10:68 Page 9 of 13be conducted on all interview data [26,27] using NVivo
qualitative analysis software.Aim 3: economic evaluation
Cost-effectiveness of a program and its net impact on
healthcare budget are important factors for decision
makers that are considering implementing new pro-
grams. Therefore, an economic analysis of the VA DPP
will be conducted to inform decision makers about im-
plementation of the VA DPP in the VA. A combination
of approaches in the economic analysis will be used. A
direct measurement micro-costing approach will be used
to assess program-related costs. In addition, modeling
will estimate long-term resource-utilization costs and
health outcomes. Together, this will estimate the incre-
mental cost-effectiveness of the VA DPP [31] and create
a complete picture of VA expenditures and health events
over time among Veterans with prediabetes. The cost re-
sults from this VA study population will then be used to
extrapolate the overall budget impact if the VA DPP is
implemented for all Veterans with prediabetes in the VA
healthcare system.Evaluation framework
The recommendations of the Panel on Cost-effectiveness
in Health and Medicine appointed by the US Public
Health Service on the Reference Case approach will guide
the cost and cost-effectiveness analyses [32]. The Refer-
ence Case approach requires that the cost-effectiveness
analysis be conducted from the societal perspective and
use a time horizon long enough to adequately capture im-
portant future benefits, harms, and costs that occur due to
program implementation, where health outcomes and
resource utilization changes of all relevant stakeholders
are taken into consideration. The Reference Case ap-
proach dictates that morbidity and mortality be reflected
in a single measure, the quality-adjusted life year (QALY),
and that future costs and QALYs be discounted to present
value.
The principles of good practice for budget impact ana-
lysis outlined by the International Society of Pharmacoe-
conomics and Outcomes Research (ISPOR) Task Force
will be followed in the budget impact analysis [33], as
done in previous VA studies [34,35]. The budget analysis
will primarily focus on short-term costs and will take
into consideration resource constraints and limitations
in the health system or in the patient population that
may limit the proportion of the target population served.Study participants
Participants will include VA DPP staff as well as patients
in the VA DPP at each VA DPP site.Data collection
Costs Micro-costing largely involves direct measure-
ment of the labor inputs required to conduct the VA
DPP and VA MOVE! sessions. Labor cost includes the
fixed cost of training the VA DPP coaches, as well as the
variable cost of delivering the VA DPP to each Veteran.
Additional file 8 provides a copy of the instructions and
log sheet that will be used by VA DPP staff to log their
activity time. The training and clinical demonstration-
related time for each staff member will be multiplied by
his or her respective wage rate (including fringe benefits),
aggregated, and then divided by the number of patients in
the VA DPP to derive per-person labor cost. Equipment
needed to deliver the VA DPP includes patient workbooks
and log books, as well as token patient incentives that are
unrelated to research survey completion, including an in-
expensive kitchen scale and water bottle.
For program cost of patients in the VA MOVE!
comparison group, the costs of VA MOVE!-specific
visits from the VA’s Managerial Cost Accounting System
(MCAS) outpatient extract file will be collected; VA
MOVE! visits can be directly identified by a clinic identi-
fier in VA claims.
The VA healthcare system also incurs substantial indir-
ect costs, such as administrative costs, janitorial services,
and utilities, which are not specific to a health service.
An indirect cost multiplier using the total indirect and
direct cost variables in the VA’s MCAS extract file will
be calculated and applied to the above direct cost esti-
mates to derive total (direct + indirect) cost. Health-care
resource utilization and costs incurred by patients dur-
ing the period they were enrolled in the program will be
extracted from the MCAS outpatient, inpatient, and
pharmacy extract files located in the VA’s Corporate
Data Warehouse (CDW).
Effectiveness Following the recommendations of the
Panel on Cost-effectiveness in Health and Medicine,
QALYs will be used as the effectiveness measure [32]. Util-
ity values will be measured using the EuroQOL EQ-5D-5
L (EQ5D) in baseline and follow-up program surveys to
calculate QALYs during the study period [36]. Additional
file 5 provides a copy of the EQ5D survey. The EQ5D asks
patients to rate their quality-of-life for the following five
dimensions: mobility, self-care, usual activities, pain or
discomfort, and anxiety or depression. There are five
statements for each domain describing increasing levels of
disability; patients are asked to choose the statement that
best represents their quality-of-life for that dimension.
Based on previous research by the EuroQoL group,
country-specific valuation sets have been derived from the
general population that allow the responses elicited by the
EQ5D to be converted into utility values [37]. The US
EQ5D value set will be used in the analysis.
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tive statistics, univariate analysis, and bivariate compari-
sons of the VA DPP and VA MOVE! session costs and
the utility values derived by the EQ5D. A lifetime time-
frame for the cost-effectiveness analysis will be adopted
because the impact of the VA DPP is not likely to mani-
fest until many years in the future. The incremental
cost-effectiveness ratio (ICER) will be calculated as the
difference in the cost per Veteran between the VA DPP
and VA MOVE! groups, divided by the difference in the
QALYs per Veteran in both groups. As recommended by
the Panel on Cost-effectiveness in Health and Medicine,
future costs will be deflated to present value and costs
and QALYs will be discounted by 3% to represent
current year equivalency [32].
The CDC-RTI Diabetes Cost-Effectiveness Markov
model (CDC-RTI model) will be used to estimate the
ICER of the VA DPP and VA MOVE!. The CDC-RTI
model is a well-validated model for estimating lifetime
costs and outcomes associated with diabetes and its
concomitant comorbidities [38]. The CDC-RTI model is
a Markov simulation model that estimates disease pro-
gression and cost-effectiveness for type 2 diabetes and
was used to assess cost-effectiveness in the original DPP
study [38]. In the CDC-RTI model, progression between
disease health states is dictated by the transition prob-
abilities that depend on risk factors including glycemic
control (measured by A1c), duration of diabetes, and
blood pressure, as well as other patient and clinical
characteristics. The VA DPP and VA MOVE! group will
differentially affect these transition probabilities and
resulting complications. Initial inputs in the CDC-RTI
model will include patient characteristics, changes in
A1c and blood pressure, program, and healthcare
utilization costs, and the utility values discussed above.
The model will then simulate development of common
complications of diabetes, such as nephropathy, neur-
opathy, retinopathy, coronary heart disease, and stroke.
CDC-RTI model outcomes will include complications,
deaths, costs, QALYs, and the ICER. Monte Carlo simu-
lation of the model will allow for consideration of a
range of model parameter values. This will generate a
95% confidence interval around the ICER point estimate.
In addition, a series of one-way sensitivity analyses to
assess the robustness of the results will be conducted to
identify which model parameters are most sensitive to
changes and thus driving the results.
The budget impact analysis will use epidemiologic
evidence from the literature [31,39] and projections
provided by the VA Office of Policy and Planning [40,41]
to estimate the proportion of the Veteran population
that receives their care from the VA healthcare system
who are likely to have prediabetes. These analyses
must also factor in real-world complications of programimplementation, such as resource constraints or potential
lack of Veteran engagement or adherence to the VA DPP.
Therefore, a sensitivity analysis will be included to esti-
mate the budget impacts of different proportions of the
Veteran population with prediabetes being serviced by the
VA DPP.
Discussion
This research study will be unique in its innovative
partnership and pragmatic evaluation design, which
includes three aims: evaluating implementation, assessing
weight and A1c outcomes, and determining the cost-
effectiveness and budget impact of implementation and
administration of the VA DPP in the VA. Design trade-offs
were assessed and balanced to meet the need for both
external and internal validity; the study will determine
if it is feasible to implement the VA DPP on a large
scale and if the VA DPP achieves expected outcomes
for Veterans. The interplay between the VA DPP im-
plementation and administration (the clinical quality
improvement component) and the VA DPP evaluation
(the research component) will present unique benefits
as well as challenges.
Because the DPP has a strong evidence base, it is ap-
propriate to prioritize maximization of external validity.
Due to the infeasibility of obtaining individual patient
consent and randomization in a clinical setting, assess-
ment of the VA DPP weight outcomes will rely on a
population-based non-randomized study design. This
design was chosen because it provides an acceptable
degree of internal validity given pragmatic constraints.
The evaluation will determine the infrastructure
needed to implement and administer the VA DPP, es-
pecially within the context of the existing VA MOVE!
program. This approach will enable the use of exist-
ing clinical screening and referral processes for VA
MOVE!. Attention to external validity considerations
will result in a sustainable program that the VA can run
on a national scale, which may mean building on exist-
ing infrastructure, rather than focusing on the VA
DPP in isolation.
The research coordinating center’s close working part-
nership with NCP will enable them to leverage funding
from multiple sources. NCP will provide a clinical opera-
tions budget to fund the VA DPP implementation and
administration. The research coordinating center will
augment this funding with research grant money to fund
the VA DPP evaluation. The partner- and implementation-
focused research funding program in VA promotes this
kind of work.
However, there will be regulatory challenges. Five
separate IRB approvals from the three VA DPP sites, the
research coordinating center, and the site conducting the
cost analyses will be required. The time needed to obtain
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implementing the VA DPP and starting to recruit the
first patients, and it will be imperative that necessary
approvals are in place before the first baseline survey
can be administered. The tension between the two time-
frames will be especially challenging to manage in the
early phases of the VA DPP implementation. It will be
important to devote considerable time for education and
dialogue with IRB administrators to negotiate boundar-
ies between clinical QI data and research data. In
addition, study protocols need to be established to en-
able access to the clinical QI data for research purposes
as needed. This confusion may extend to VA DPP staff
as well; frequent and ongoing discussions will occur to
elucidate whether VA DPP staff members will be act-
ing with their clinical or research “hat” on. For ex-
ample, patient assessment for eligibility for the VA
DPP will be considered a clinical activity while administer-
ing a baseline survey to patients will be considered
research.
The use of multiple data sources will provide a de-
tailed understanding how the VA DPP should be imple-
mented nationally as well as the effectiveness of the VA
DPP. The use of the CFIR and RE-AIM frameworks to
guide data collection and analysis for the formative
evaluation will provide an efficient approach for asses-
sing and reporting findings to NCP and the VA DPP
sites. Deductive and inductive analysis ensures consider-
ation of themes or findings outside of these frameworks,
which will help bolster validity of findings. Collecting in-
formation about fidelity and characteristics of program
delivery will allow for comparison of the programs,
as well as assessment of potential association with
weight and A1c outcomes. The combination of quali-
tative and quantitative data elicited from patients will
reveal greater insights about patient experiences with
both programs.Conclusion
This study is unique in highlighting the tremendous
rewards and unique challenges of conducting research in
close partnership with clinical leaders. Findings from this
pragmatic evaluation will be highly applicable to practi-
tioners who are tasked with implementing the DPP in
clinical settings. In addition, findings will determine the
effectiveness and cost-effectiveness of the VA DPP in the
Veteran population.Trial status
Trial status at the time of manuscript submission is
ongoing. Patients have been recruited, and baseline assess-
ments are complete. Data cleaning or analysis of 12-month
summative outcomes has not been started.Additional files
Additional file 1: VA DPP and VA MOVE! program design
differences. This file provides an outline of how the VA DPP and VA
MOVE! differ.
Additional file 2: Research questions and RE-AIM measures. This file
provides a detailed list of research questions and quantitative and
qualitative measures for RE-AIM domains.
Additional file 3: Staff interview guides. This file provides a copy of
the master interview guides (early and late implementation) used to
interview staff.
Additional file 4: Session delivery fidelity checklists for the VA DPP
and VA MOVE!. This file includes copies of fidelity checklists used to
assess VA DPP fidelity to the GLB program and to compare VA DPP
sessions to VA MOVE! sessions.
Additional file 5: Program and EuroQOL EQ-5D-5 L surveys. This file
provides a copy of the program and EuroQOL EQ-5D-5 L surveys.
Additional file 6: Patient interview guide. This file provides a copy of
the master interview guide used to interview patients.
Additional file 7: Mediation analyses. This file describes the mediation
analyses in the “Aim 2” section.
Additional file 8: Cost-effectiveness assessment instructions and
log. This file provides a description and instructions for staff to use to log
their time.
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